Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Zacks

Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab

Pfizer (NYSE:PFE) and its partner, BioNTech (NASDAQ:BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for their Omicron-adapted bivalent COVID-19 vaccine candidate in individuals aged 12 years and older.

The bivalent vaccine is a combination of Pfizer/BioNTech's currently marketed COVID-19 vaccine, Comirnaty and a vaccine candidate targeting the spike protein of the Omicron BA.1 subvariant. The regulatory filing by Pfizer and BioNTech follows the guidelines laid down by both the EMA and the International Coalition of Medicines Regulatory Authorities to develop Omicron-specific vaccines for tackling the problem of new and evolving COVID-19 variants.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.